A 66-year-old man with metastatic pancreatic adenocarcinoma and a new portal vein thrombosis
A 66-year-old man has metastatic pancreatic ductal adenocarcinoma with liver metastases, diagnosed 3 months ago. He completed 4 cycles of FOLFIRINOX with partial response but has significant grade 2 peripheral neuropathy and fatigue. He now presents with abdominal pain and melena. CT shows a new thrombus in the portal vein and a cavernous transformation, plus a small bowel lesion. He has a hemoglobin of 7.9 g/dL, platelets of 88,000/µL, INR of 1.4, and a creatinine of 1.1 mg/dL. He is not actively bleeding but has had intermittent melena. He asks about anticoagulation and about continuing chemotherapy.
1. How would you approach anticoagulation in this patient with cancer-associated portal vein thrombosis and recent melena?
Read the worked answer
This requires balancing thrombosis and bleeding risk.
- Assess bleeding source: The melena and small bowel lesion raise concern for a bleeding source (e.g., tumor invasion, ulcer, or angiodysplasia). Endoscopy should be considered when safe, and the small bowel lesion should be evaluated.
- Anticoagulation choice: For cancer-associated thrombosis, low-molecular-weight heparin (LMWH) or a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban is generally preferred over warfarin. However, in portal vein thrombosis with cavernous transformation and recent GI bleeding, anticoagulation is high-risk and should be individualized.
- Acute setting: With active melena and hemoglobin 7.9 g/dL, hold anticoagulation until bleeding is controlled and the source is identified; transfuse as needed and correct reversible factors.
- Chronic setting: If bleeding is controlled and the thrombus is symptomatic or extending, LMWH may be safer than a DOAC given the GI bleed history. Duration is typically at least 3–6 months, with reassessment.
- Platelets 88,000/µL are adequate for most procedures but warrant caution with full anticoagulation.
- Multidisciplinary input (GI, hematology, oncology) is appropriate.
2. What chemotherapy options remain after FOLFIRINOX, given his neuropathy?
Read the worked answer
Options include:
- Gemcitabine plus nab-paclitaxel: a standard first-line or subsequent regimen; however, nab-paclitaxel can worsen neuropathy, so dose modification or substitution may be needed.
- Gemcitabine monotherapy: reasonable if performance status or toxicity limits combination therapy.
- Liposomal irinotecan plus 5-FU/leucovorin: approved after gemcitabine-based therapy; it avoids platinum and taxane neuropathy but can cause diarrhea and myelosuppression.
- Capecitabine or 5-FU/leucovorin as palliative options.
- Given grade 2 neuropathy, avoid further platinum and taxane where possible, and consider dose reduction of oxaliplatin if FOLFIRINOX is continued.
- Molecular testing (e.g., BRCA1/2, MSI-H/dMMR, NTRK, KRAS G12C) should be reviewed; if BRCA-mutated, a PARP inhibitor or platinum sensitivity may inform choices, and if MSI-H, immunotherapy is an option.
- Goals of care and quality of life should guide selection.
3. What supportive care measures are important in this patient?
Read the worked answer
Supportive care should address symptoms, nutrition, and goals:
- Pain control: Multimodal analgesia for abdominal pain, with attention to constipation and renal function.
- Anemia: Transfuse for symptomatic anemia; evaluate iron studies and the source of blood loss.
- Nutrition: Pancreatic enzyme replacement for exocrine insufficiency, dietitian involvement, and consideration of appetite stimulants.
- VTE prophylaxis/treatment: As above, individualized.
- Neuropathy: Dose modification, gabapentin or duloxetine for symptoms, and physical therapy.
- Psychosocial and palliative care: Early palliative care improves quality of life and mood in metastatic pancreatic cancer; discuss goals of care and advance care planning.
- Bone health: Vitamin D and calcium, and bone-modifying agents if bone metastases are present.